Lipid Nanocarriers for Enhanced Delivery of Temozolomide to the Brain.
Animals
Antineoplastic Agents, Alkylating
/ administration & dosage
Blood-Brain Barrier
Brain Diseases
/ drug therapy
Chromatography, Liquid
Drug Carriers
/ administration & dosage
Drug Delivery Systems
/ methods
Dynamic Light Scattering
Lipids
/ chemistry
Male
Microscopy, Electron, Scanning
Nanoparticles
/ administration & dosage
Particle Size
Rats
Rats, Wistar
Temozolomide
/ administration & dosage
Workflow
Blood–brain barrier
HPLC
Nanostructured lipid carriers
Pharmacokinetics
Temozolomide
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
23
8
2019
pubmed:
23
8
2019
medline:
24
11
2020
Statut:
ppublish
Résumé
Brain disorders, a diverse range of conditions comprising of neurological and psychiatric conditions, are the leading cause of disability, severely affect the quality of life, and in many cases lead to mortality. The prime challenge in treatment of brain disorders is to deliver therapeutics by overcoming the blood-brain barrier (BBB), a unique anatomical and physiological barrier which restricts the passage of a number of molecules, proteins, and cells from the bloodstream. Lipid nanoparticles have emerged as promising drug delivery systems primarily because of biodegradability, low toxicity potential, and the ability to cross physiological barriers especially the BBB even without surface modifications.In this chapter we discuss the preparation and characterization of nanostructured lipid carriers of temozolomide, a chemotherapeutic drug. Evaluation of pharmacokinetics and biodistribution of the nanocarrier system in rats revealed improved delivery of the chemotherapeutic agent to the brain with the potential of lesser side effects.
Identifiants
pubmed: 31435928
doi: 10.1007/978-1-4939-9798-5_15
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Drug Carriers
0
Lipids
0
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM